Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wan-Long Chuang

Showing results (131-140 of 456) with videos related to

Pageof 46
Sort By:
Hepatology International|February 3, 2011
Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in TaiwanJeng-Fu Yang, Yi-Hui Kao, Chia-Yen Dai, et al.
Journal of Hepatology|February 24, 2009
Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patientsChia-Yen Dai, Jee-Fu Huang, Ming-Yen Hsieh, et al.
Plos One|November 6, 2018
Association of hyperuricemia with disease severity in chronic hepatitis C patientsTyng-Yuan Jang, Ming-Lun Yeh, Ching-I Huang, et al.
Plos One|April 4, 2015
Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patientsMing-Lun Yeh, Cheng-Yuan Peng, Chia-Yen Dai, et al.
Hepatology International|November 15, 2018
Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antiviralsChung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, et al.
Hepatology International|July 24, 2015
Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremicsChung-Feng Huang, Ming-Lun Yeh, Jia-Jung Lee, et al.
The Kaohsiung Journal of Medical Sciences|November 17, 2016
Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter studyMing-Lun Yeh, Ching-I Huang, Ming-Yen Hsieh, et al.
International Journal of Medical Sciences|April 2, 2014
Discrepancy between serological and virological analysis of viral hepatitis in hemodialysis patientsJer-Ming Chang, Chung-Feng Huang, Szu-Chia Chen, et al.
BMC Infectious Diseases|April 13, 2005
High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort studyMing-Lung Yu, Chia-Yen Dai, Shinn-Cherng Chen, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 9, 2022
Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinomaZu-Yau Lin, Ming-Lun Yeh, Ching-I Huang, et al.
Pageof 46

Showing results (131-140 of 456) with videos related to

Sort By:
Pageof 46
Hepatology International|February 3, 2011
Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in TaiwanJeng-Fu Yang, Yi-Hui Kao, Chia-Yen Dai, et al.
Journal of Hepatology|February 24, 2009
Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patientsChia-Yen Dai, Jee-Fu Huang, Ming-Yen Hsieh, et al.
Plos One|November 6, 2018
Association of hyperuricemia with disease severity in chronic hepatitis C patientsTyng-Yuan Jang, Ming-Lun Yeh, Ching-I Huang, et al.
Plos One|April 4, 2015
Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patientsMing-Lun Yeh, Cheng-Yuan Peng, Chia-Yen Dai, et al.
Hepatology International|November 15, 2018
Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antiviralsChung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, et al.
Hepatology International|July 24, 2015
Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremicsChung-Feng Huang, Ming-Lun Yeh, Jia-Jung Lee, et al.
The Kaohsiung Journal of Medical Sciences|November 17, 2016
Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter studyMing-Lun Yeh, Ching-I Huang, Ming-Yen Hsieh, et al.
International Journal of Medical Sciences|April 2, 2014
Discrepancy between serological and virological analysis of viral hepatitis in hemodialysis patientsJer-Ming Chang, Chung-Feng Huang, Szu-Chia Chen, et al.
BMC Infectious Diseases|April 13, 2005
High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort studyMing-Lung Yu, Chia-Yen Dai, Shinn-Cherng Chen, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 9, 2022
Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinomaZu-Yau Lin, Ming-Lun Yeh, Ching-I Huang, et al.
Pageof 46